INTRABIO

Dead / Abandoned — Abandoned — failure to respond (as of 10 Jan 2019)

What this means for you

This application is over — abandoned 17 Dec 2018. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
79232153
Mark type
Stylized text
Filed
14 Feb 2018
Abandoned
17 Dec 2018

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; drugs for medical purposes; drugs for medical purposes, namely, the prevention and treatment of neurodegenerative diseases; drugs for medical purposes, namely, the prevention and treatment of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; reagents for use in medical genetic testing; diagnostic reagents for medical laboratory use; diagnostic reagents for medical laboratory use, namely, use in the detection and identification of neurodegenerative diseases; diagnostic reagents for medical laboratory use, namely, use in the detection and identification of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; amino acid preparations for medical purposes; amino acid preparations for pharmaceutical use
  • Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto; industrial analysis and research services; scientific and technological services and research in the field of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; industrial analysis and research services related to neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy, design and development of computer hardware and software related to assays; clinical trials; conducting clinical trials for pharmaceutical products; conducting clinical trials for neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; medical laboratories for research related to neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; providing information about the results of clinical trials for pharmaceutical products; clinical research; medical laboratories; research relating to molecular sciences; medical research; genetic research; research in the field of gene therapy; biopharmaceutical research for development of targeted therapies for use in the treatment of carcinomas and neurodegenerative diseases; scientific, biochemical, research and development services in the field of neurodegenerative diseases; providing scientific information in the field of medical disorders and their treatment; pharmaceutical drug development services

Owner

Prosecution history

  • 31 Jan 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
  • 10 Jan 2020 — FINAL DISPOSITION NOTICE SENT TO IB
  • 10 Jan 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
  • 08 Nov 2019 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
  • 23 Oct 2019 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
  • 23 Oct 2019 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
  • 11 Jan 2019 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
  • 10 Jan 2019 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
  • 30 Jun 2018 — REFUSAL PROCESSED BY IB
  • 14 Jun 2018 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
  • 14 Jun 2018 — REFUSAL PROCESSED BY MPU
  • 07 Jun 2018 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
  • 06 Jun 2018 — NON-FINAL ACTION WRITTEN
  • 30 May 2018 — ASSIGNED TO EXAMINER
  • 25 May 2018 — APPLICATION FILING RECEIPT MAILED

View this trademark record on Marksy